ATLAS / Macro Radar / Reporting / NUVL

Nuvalent, Inc. (NUVL) reporting calendar

Nuvalent, Inc. files periodic reports with the SEC as NUVL on Nasdaq. Atlas tracks 20 filed reports for this issuer, each linked to its original EDGAR accession.

Next window
24 Jul 2026 – 21 Aug 2026
Latest report
10-Q
Period ended
31 Mar 2026
Filed
7 May 2026
Reports on record
20

How this window is derived. Derived from this issuer's own filing history: 9 periods at a median 91-day cadence, filed a median 38 days after period end. The SEC does not publish forward reporting dates and Atlas does not estimate one.

Open NUVL market profile Latest filing on SEC EDGAR ↗ Pharmaceutical Preparations reporting datesAll Nasdaq reporting dates

Filed periodic reports

FormPeriod endedFiledLagSEC accession
10-Q31 Mar 20267 May 202637 days0001861560-26-000021
10-K31 Dec 202526 Feb 202657 days0001193125-26-073317
10-Q30 Sep 202530 Oct 202530 days0001193125-25-257357
10-Q30 Jun 20257 Aug 202538 days0000950170-25-104532
10-Q31 Mar 20258 May 202538 days0000950170-25-066401
10-K31 Dec 202427 Feb 202558 days0000950170-25-028328
10-Q30 Sep 202412 Nov 202443 days0000950170-24-124518
10-Q30 Jun 20248 Aug 202439 days0000950170-24-093285
10-Q31 Mar 20249 May 202439 days0000950170-24-056232
10-K31 Dec 202327 Feb 202458 days0000950170-24-020607
10-Q30 Sep 202314 Nov 202345 days0000950170-23-063341
10-Q30 Jun 202310 Aug 202341 days0000950170-23-040937
10-Q31 Mar 202311 May 202341 days0000950170-23-020807
10-K31 Dec 202216 Mar 202375 days0000950170-23-008284
10-Q30 Sep 202210 Nov 202241 days0000950170-22-024138
10-Q30 Jun 202210 Aug 202241 days0001193125-22-216780
10-Q31 Mar 202212 May 202242 days0001193125-22-148022
10-K31 Dec 202129 Mar 202288 days0001193125-22-087401
10-Q30 Sep 202110 Nov 202141 days0001193125-21-325215
10-Q30 Jun 20218 Sep 202170 days0001193125-21-267350

Source: SEC EDGAR company submissions for CIK 0001861560. Atlas publishes filed facts only. The SEC does not publish forward reporting dates, so no announced future date is claimed here.